Description
Iteos Therapeutics is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients with cancer.
The Company's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant. The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression.
Its inupadenant, is an adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment. The Company is conducting an open-label multi-arm Phase I/IIa clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
